BioNTech’s mRNA Cancer Therapy Misses First Goal in Head and Neck Trial

Handelsblatt

Lean Right

Factuality

Ownership

In the case of head and neck cancer, mRNA immunotherapy did not stop the disease from progressing. Nevertheless, the Mainzians do not see a definitive outcome.

byc-news.de

Factuality

Ownership

Another setback for the Mainz-based biopharma company BioNTech: In an important late-stage study for the treatment of head and neck cancer, the hope bearer BNT113 missed one of its main objectives. Despite the damper, the researchers continued the study to investigate the overall survival of patients. As the company announced, the mRNA-based therapy candidate BNT113 was able to continue the study in a clinical phase 3 study [...] Der Beitrag Dam…